Search - tctmd.com

Displaying 161 - 180 of 1554

Sort: Relevancy | Date

Presentation THT 2025

When and Why Are Diuretics Sometimes Just Not Enough?

Presenter: Jennifer Cowger

February 12, 2025

Presentation THT 2025

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Presenter: Barry Borlaug

February 11, 2025

Presentation THT 2025

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Presenter: Javed Butler

February 11, 2025

Presentation THT 2025

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) – The FASTR Trial

Presenter: James Udelson

February 11, 2025

Presentation THT 2025

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Presenter: Gregg W. Stone

February 11, 2025

Presentation THT 2025

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Presenter: Sanjiv Shah

February 11, 2025

Presentation THT 2025

Strategy to Prevent Cardiogenic SHOCK: Randomised Clinical Trial (STOPSHOCK - RCT)

Presenter: Allan Böhm

February 11, 2025

Presentation THT 2025

Drug Therapy to Improve Shock Outcomes: The Emerging DPP3 Story

Presenter: Mahir Karakas

February 11, 2025

Presentation THT 2025

Harnessing Real World Data to Test Emerging Technologies

Presenter: Robert Yeh

February 11, 2025

Presentation THT 2025

Time to Escalation: From the Golden Day to the Golden Six Hours

Presenter: Elric Zweck

February 11, 2025

Presentation THT 2025

Cardiogenic Shock in the Post-DanGer Shock Trial Era

Presenter: Shelley Hall

February 11, 2025

Presentation THT 2025

Optimizing Outcomes in Cardiac Arrest and Shock

Presenter: Jacqueline Tamis-Holland

February 11, 2025

Presentation THT 2025

Special Late-Breaking Clinical Science Abstract: Hemodynamic Effects of Intravenous Istaroxime in Patients With SCAI Stage B Cardiogenic Shock: Insights From the SEISMiC Trial

Presenter: Matteo Pagnesi

February 11, 2025

Presentation THT 2025

Only Select Patients Should Have a PA Pressure Sensor

Presenter: Maria Rosa Costanzo

February 11, 2025

Presentation THT 2025

All NYHA III Patients Should Have a PA Pressure Sensor

Presenter: Michael Givertz

February 11, 2025

Presentation THT 2025

Preserving Access: Limiting the Use of Advanced Therapies

Presenter: Gerin Stevens

February 11, 2025

Presentation THT 2025

Increasing Access: Using Team-Based Care to Get STRONG

Presenter: Laura Cohen

February 11, 2025

Presentation THT 2025

Evidence Is Getting STRONGer That Rapid GDMT Uptitration After an AHF Event Is Effective Regardless of LVEF

Presenter: Gad Cotter

February 11, 2025

Presentation THT 2025

Increasing Reach: Using TeleHealth to Get STRONGer

Presenter: Daniel Bensimhon

February 11, 2025

Presentation THT 2025

Increasing Access: Reducing Referral Delay in Ambulatory Advanced HF Patients

Presenter: Nir Uriel

February 11, 2025

Advertisement

When and Why Are Diuretics Sometimes Just Not Enough?

Impact of Obesity Severity on the Effects of Tirzepatide in HFpEF: The SUMMIT Trial

Left Atrial to Coronary Sinus Shunting in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: The ALT FLOW Trial (Early Feasibility Study) 2-Year Results

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve Decongestion Management System (DMS) – The FASTR Trial

Predictors of Outcomes After Inter-atrial Shunt Treatment in HFrEF and HFpEF: The RELIEVE-HF trial

Atrial Shunt for Heart Failure With Preserved and Mildly Reduced Ejection Fraction: Five-Year Outcomes in the REDUCE LAP-HF II Trial

Strategy to Prevent Cardiogenic SHOCK: Randomised Clinical Trial (STOPSHOCK - RCT)

Drug Therapy to Improve Shock Outcomes: The Emerging DPP3 Story

Harnessing Real World Data to Test Emerging Technologies

Time to Escalation: From the Golden Day to the Golden Six Hours

Cardiogenic Shock in the Post-DanGer Shock Trial Era

Optimizing Outcomes in Cardiac Arrest and Shock

Special Late-Breaking Clinical Science Abstract: Hemodynamic Effects of Intravenous Istaroxime in Patients With SCAI Stage B Cardiogenic Shock: Insights From the SEISMiC Trial

Only Select Patients Should Have a PA Pressure Sensor

All NYHA III Patients Should Have a PA Pressure Sensor

Preserving Access: Limiting the Use of Advanced Therapies

Increasing Access: Using Team-Based Care to Get STRONG

Evidence Is Getting STRONGer That Rapid GDMT Uptitration After an AHF Event Is Effective Regardless of LVEF

Increasing Reach: Using TeleHealth to Get STRONGer

Increasing Access: Reducing Referral Delay in Ambulatory Advanced HF Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content